Investigation into the protective effects of hypaconitine and glycyrrhetinic acid against chronic heart failure of the rats
© 2022. The Author(s)..
BACKGROUND: The present study aimed to determine the protective effects of hypaconitine (HA) and glycyrrhetinic acid (GA) against chronic heart failure (CHF) in the rats and to explore the underlying molecular mechanisms.
METHODS: The CHF rat model was established by transverse-aortic constriction (TAC) operation. Transthoracic echocardiography and hematoxylin eosin (HE) staining were used to evaluate the pathophysiological and histopathological changes of CHF model. The total cholesterol (TCHO) and triglyceride (TG) levels were determined by ELISA assay. The protein expression of fibroblast growth factor 2 (FGF2), vascular endothelial growth factor A (VEGFA) and endothelial nitric oxide synthase (eNOS) in the rat ventricular tissues was determined by immunohistochemistry. The serum metabolites were determined by LC-MS/MS assay.
RESULTS: After applied the HA + GA, the cardiac tissue and structure were obviously improved, and the HA + GA treatment also significantly reduced the plasma levels of TCHO and TG in the CHF rats. The expression of FGF2 and VEGFA protein was up-regulated and the expression of eNOS protein was down-regulated in the ventricular tissues of CHF rats, which was significantly restored after HA + GA treatment. HA + GA treatment down-regulated serum isonicotinic acid, phosphatidylcholine, cardiolipin, estrogen glucuronide, and glycocholic acid, up-regulated serum sphingosine and deoxycholic acid in the CHF rats.
CONCLUSIONS: In conclusion, HA + GA showed protective effects on CHF in the rats, and the HA + GA may exert protective effects by reducing lipid levels, up-regulating the expression of FGF2 and VEGFA proteins, attenuating eNOS protein expression, and modulating metabolic pathways. However, the molecular mechanisms underlying HA + GA-mediated effects still require further examination.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
BMC complementary medicine and therapies - 22(2022), 1 vom: 16. Juni, Seite 160 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Liqin [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 20.06.2022 Date Revised 16.07.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12906-022-03632-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM342317490 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM342317490 | ||
| 003 | DE-627 | ||
| 005 | 20231226013830.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12906-022-03632-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1141.xml |
| 035 | |a (DE-627)NLM342317490 | ||
| 035 | |a (NLM)35710396 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Liqin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Investigation into the protective effects of hypaconitine and glycyrrhetinic acid against chronic heart failure of the rats |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.06.2022 | ||
| 500 | |a Date Revised 16.07.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a BACKGROUND: The present study aimed to determine the protective effects of hypaconitine (HA) and glycyrrhetinic acid (GA) against chronic heart failure (CHF) in the rats and to explore the underlying molecular mechanisms | ||
| 520 | |a METHODS: The CHF rat model was established by transverse-aortic constriction (TAC) operation. Transthoracic echocardiography and hematoxylin eosin (HE) staining were used to evaluate the pathophysiological and histopathological changes of CHF model. The total cholesterol (TCHO) and triglyceride (TG) levels were determined by ELISA assay. The protein expression of fibroblast growth factor 2 (FGF2), vascular endothelial growth factor A (VEGFA) and endothelial nitric oxide synthase (eNOS) in the rat ventricular tissues was determined by immunohistochemistry. The serum metabolites were determined by LC-MS/MS assay | ||
| 520 | |a RESULTS: After applied the HA + GA, the cardiac tissue and structure were obviously improved, and the HA + GA treatment also significantly reduced the plasma levels of TCHO and TG in the CHF rats. The expression of FGF2 and VEGFA protein was up-regulated and the expression of eNOS protein was down-regulated in the ventricular tissues of CHF rats, which was significantly restored after HA + GA treatment. HA + GA treatment down-regulated serum isonicotinic acid, phosphatidylcholine, cardiolipin, estrogen glucuronide, and glycocholic acid, up-regulated serum sphingosine and deoxycholic acid in the CHF rats | ||
| 520 | |a CONCLUSIONS: In conclusion, HA + GA showed protective effects on CHF in the rats, and the HA + GA may exert protective effects by reducing lipid levels, up-regulating the expression of FGF2 and VEGFA proteins, attenuating eNOS protein expression, and modulating metabolic pathways. However, the molecular mechanisms underlying HA + GA-mediated effects still require further examination | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Chronic heart failure | |
| 650 | 4 | |a Glycyrrhetinic acid | |
| 650 | 4 | |a Hypaconitine | |
| 650 | 4 | |a Immunohistochemistry | |
| 650 | 4 | |a Metabolites | |
| 650 | 7 | |a Vascular Endothelial Growth Factor A |2 NLM | |
| 650 | 7 | |a Fibroblast Growth Factor 2 |2 NLM | |
| 650 | 7 | |a 103107-01-3 |2 NLM | |
| 650 | 7 | |a hypaconitine |2 NLM | |
| 650 | 7 | |a 5207313N6E |2 NLM | |
| 650 | 7 | |a Glycyrrhetinic Acid |2 NLM | |
| 650 | 7 | |a P540XA09DR |2 NLM | |
| 650 | 7 | |a Aconitine |2 NLM | |
| 650 | 7 | |a X8YN71D5WC |2 NLM | |
| 700 | 1 | |a Deng, Haiming |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Tengyu |e verfasserin |4 aut | |
| 700 | 1 | |a Qiao, Yun |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Jianbing |e verfasserin |4 aut | |
| 700 | 1 | |a Xiong, Mingfeng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC complementary medicine and therapies |d 2020 |g 22(2022), 1 vom: 16. Juni, Seite 160 |w (DE-627)NLM306156547 |x 2662-7671 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2022 |g number:1 |g day:16 |g month:06 |g pages:160 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12906-022-03632-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2022 |e 1 |b 16 |c 06 |h 160 | ||